Recursion therapeutics stock
WebApr 11, 2024 · Recursion Pharmaceuticals, stock has received a consensus rating of hold. The average rating score is and is based on 5 buy ratings, 10 hold ratings, and 0 sell ratings. WebApr 14, 2024 · Esperion Therapeutics Inc (ESPR) stock is trading at $1.21 as of 11:29 AM on Friday, Apr 14, a drop of -$0.14, or -10.37% from the previous closing price of $1.35. The stock has traded between $1.21 and $1.35 so far today. Volume today is light. So far 949,750 shares have traded compared to average volume of 6,452,500 shares.
Recursion therapeutics stock
Did you know?
WebDec 7, 2024 · Recursion will work with both Roche and Genentech's R&D units to leverage technology-enabled drug discovery through the Recursion Operating System (OS) to more rapidly identify novel targets and ... WebRecursion Pharmaceuticals Inc Follow Share $7.43 After Hours: $7.43 (0.00%) 0.00 Closed: Mar 21, 4:01:10 PM GMT-4 · USD · NASDAQ · Disclaimer search Compare to Pfizer Inc. $40.66 PFE0.37% NVIDIA...
WebApr 11, 2024 · According to analysts, Recursion Pharmaceuticals's stock has a predicted upside of 36.20% based on their 12-month price targets. What analysts cover Recursion Pharmaceuticals? Recursion Pharmaceuticals has been rated by Needham & Company LLC, and SVB Leerink in the past 90 days. Stock Ratings Reports and Tools Apple Meta … WebMar 31, 2024 · RECURSION PHARMACEUTICALS, INC. : Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information Nasdaq: RXRX Nasdaq RECURSION PHARMACEUTICALS, INC.
WebMar 28, 2024 · Recursion is the clinical-stage biotechnology company industrializing drug discovery by decoding biology. Enabling its mission is the Recursion OS, a platform built … WebApr 7, 2024 · Recursion Pharmaceuticals Inc stock has a Growth Score of 27, Momentum Score of 63 and Quality Score of 17. Comparing Denali Therapeutics Inc and Recursion …
WebApr 27, 2024 · Recursion Pharmaceuticals Inc. uses machine learning to hunt for new therapies. ... REC-259618,and REC-648647) with the potential to be orally bioavailable, CNS-penetrant, disease modifying therapeutics for multiple subtypes of Batten disease. ... investors are advised that past stock performance is not indicative of future price action.
WebApr 12, 2024 · Recursion Pharmaceuticals (NASDAQ:RXRX) has filed to raise $306 million in an IPO of its Class A common stock, according to an S-1 registration statement. The firm … greystar walnut creekWebFind the latest Tango Therapeutics, Inc. (TNGX) stock quote, history, news and other vital information to help you with your stock trading and investing. greystar warriorsWebRecursion Pharmaceuticals started at buy with $31 stock price target at BofA Securities May. 11, 2024 at 9:44 a.m. ET by Tomi Kilgore Recursion Pharmaceuticals started at … field museum calendarWebJul 13, 2024 · SALT LAKE CITY, July 13, 2024 - Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced its formation of a Therapeutics Advisory Board (TAB), chaired by Joseph Miletich, MD, PhD. … greystar webmailWebWe operate at the intersection and cutting-edge of science and technology. Unlike traditional biotechnology companies, our rapidly growing team of more than 200 Recursionauts is … field museum chicago discountWebMar 16, 2024 · In a report released today, Gil Blum from Needham initiated coverage with a Buy rating on Recursion Pharmaceuticals and a price target of $17.00. The company’s … greystar wembleyfield museum camp